Coinciding with this year’s International Nurses Day, this week’s Federal Budget has had some significant outcomes for the primary health care, nursing workforce.
The Federal Budget delivered on 9th May 2023, APNA believes will strengthen Australia’s primary health care (PHC) system by addressing growing nursing shortages, seeing more nurses hired where they are needed, and better utilising the largest workforce in PHC of nearly 100,000 nurses to their full potential to reduce the pressure on the health system.
The Federal Budget could significantly boost job prospects and career progression in primary healthcare, as well as strengthen the current PHC nursing workforce by funding:
- An 18-month national Scope of Practice review
- 6,000 additional clinical placements in primary healthcare nursing ($4.2 million over four years)
- 1,850 graduate scholarships to train more Nurse Practitioners ($50.2 million over four years)
- $1 million towards incentives to get 500 nurses back into the workforce
Australian Health Journal met with APNA President Karen Booth and CEO Ken Griffin at their Money in May 2023 event in Sydney.
Money in May is an APNA member-only initiative and is a month of education so that nurses know more about money and how to navigate the financial side of being a nurse. The campaign has three key themes: do more, save more and earn more.
Timed to coincide with the end of the financial year, APNA has focused on financial literacy. Nurses who understand the opportunities and challenges of finance and funding mechanisms and keep abreast of changes can be an even greater asset for their patients and the business they work for. For their personal lives, they make better financial decisions, earn more and retire with more super.
The outcomes are for each Primary healthcare nurse in a time to influence and pitch for what they want — be that money to fund a nurse-led clinic, a financial allocation for CPD or negotiate pay.
Relating that back to the funding announcements in the Federal Budget, there is potential to significantly boost job prospects and career progression in primary healthcare, as well as strengthen the current PHC nursing workforce.
-
Cardinal Health brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.
-
Patient family develops app for improved adherence and clinical outcomes
Darron Goralsky, a physiotherapist with over 30 years of experience, is the Clinical Director and Founder of Melbourne TMJ and Facial Pain Centre. He leads a multidisciplinary team dedicated to treating jaw pain, facial pain, and headaches. Goralsky has observed a rise in musculoskeletal issues among younger populations, largely due to increased screen time and poor posture, trends that intensified during the COVID-19 pandemic. Emphasising technology integration and patient responsibility, he believes digital health solutions play a crucial role in improving adherence and outcomes for both patients and caregivers.
-
Using human skin hair follicles to treat Alzheimer’s disease
Professor Michael Valenzuela is a science opinion leader, innovator and creative thinker with a career-long commitment to the prevention and treatment of dementia.
Following that he completed graduate medicine and medical training at the Prince of Wales Hospital. In 2012, he established the Regenerative Neuroscience Group at the University of Sydney, and in 2017 became the university’s first Professor of Regenerative Medicine.
Professor Valenzuela’s group discovered a new cell type with potential for regenerative medicine, a rare neural precursor cell found deep within the human hair follicle. He is the main inventor on several related patents and is the Founder and Chief Scientific Officer of Skin2Neuron – a biotech company developing the first neurorestorative cell therapy for Alzheimer’s disease based on this work.
